Publications by authors named "David Strutton"

Claim this Profile
P
Precision Reimbursement for Precision Medicine: Using Real-World Evidence to Evolve From Trial-and-Project to Track-and-Pay to Learn-and-Predict.
Hans-Georg Eichler, Mark Trusheim, Brigitte Schwarzer-Daum, Kay Larholt, Markus Zeitlinger, David Strutton

Clin Pharmacol Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.
Derek Weycker, Raymond A Farkouh, David R Strutton, John Edelsberg, Kimberly M Shea

BMC Health Serv Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of pneumonia among children and adults with chronic medical conditions in Germany.
Stephen I Pelton, Kimberly M Shea, Raymond A Farkouh, David R Strutton, Sebastian Braun

BMC Infect Dis· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.
Michele A Kohli, Raymond A Farkouh, Michael J Maschio, Lisa J McGarry, David R Strutton

Health Aff (Millwood)· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking risk for pneumococcal disease in adults: the role of risk stacking.
Stephen I Pelton, Kimberly M Shea, Derek Weycker, Raymond A Farkouh, David R Strutton

Open Forum Infect Dis· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine.
Stephen I Pelton, Derek Weycker, Raymond A Farkouh, David R Strutton, Kimberly M Shea

Clin Infect Dis· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of pneumococcal disease in adults with chronic medical conditions.
Kimberly M Shea, John Edelsberg, Derek Weycker, Raymond A Farkouh, David R Strutton

Open Forum Infect Dis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community-acquired pneumonia: symptoms and burden of illness at diagnosis among US adults aged 50 years and older.
Kathleen W Wyrwich, Holly Yu, Reiko Sato, David Strutton, John H Powers

Patient· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the editor.
Rogier M Klok, Rose-Marie Lindkvist, Mats Ekelund, Raymond A Farkouh, David R Strutton

Clin Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.
Lisa J McGarry, Kristen E Gilmore, Jaime L Rubin, Keith P Klugman, David R Strutton

BMC Infect Dis· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of adult pneumococcal vaccination: response to Grabenstein et al.
Derek Weycker, Reiko Sato, David Strutton, John Edelsberg, Mark Atwood

Vaccine· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Rogier M Klok, Rose-Marie Lindkvist, Mats Ekelund, Raymond A Farkouh, David R Strutton

Clin Ther· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
Raymond Farkouh, Rogier Klok, Craig Roberts, Asbjørn Mack, David Strutton

Vaccine· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.
Raymond A Farkouh, Rogier M Klok, Maarten J Postma, Craig S Roberts, David R Strutton

Expert Rev Vaccines· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years.
Derek Weycker, Reiko Sato, David Strutton, John Edelsberg, Mark Atwood

Vaccine· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.
David R Strutton, Raymond A Farkouh, Jaime L Rubin, Lisa J McGarry, Paul M Loiacono

BMC Infect Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of acute lower respiratory tract infection in South African children.
Anushua Sinha, Soyeon Kim, Gary Ginsberg, Heather Franklin, Robert Kohberger, David Strutton

Paediatr Int Child Health· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Stephanie R Earnshaw, Cheryl L McDade, Giovanni Zanotti, Raymond A Farkouh, David Strutton

BMC Infect Dis· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
David R Strutton, Raymond A Farkouh, Stephanie R Earnshaw, Sharon Hwang, Ulrike Theidel

J Infect· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries".
David Strutton, Sharon Hwang, Raymond Farkouh, Craig Roberts

Vaccine· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Emilio Muciño-Ortega, Joaquín Federico Mould-Quevedo, Raymond Farkouh, David Strutton

Value Health· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.
Jaime L Rubin, Lisa J McGarry, David R Strutton, Keith P Klugman, Stephen I Pelton

Vaccine· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and economic burden of pneumococcal disease in older US adults.
Derek Weycker, David Strutton, John Edelsberg, Reiko Sato, Lisa A Jackson

Vaccine· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
7
7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series.
Stephen I Pelton, Derek Weycker, Jerome O Klein, David Strutton, Vincent Ciuryla

Vaccine· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.
Jaime L Rubin, Lisa J McGarry, Keith P Klugman, David R Strutton, Kristen E Gilmore

BMC Infect Dis· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis